Characterizing the heterogeneity of the CD44-SPP1 axis could help to identify therapeutic strategies for patients with advanced bladder cancer.
Hiba Siddiqui, BSc
Advertisement
Articles by Hiba Siddiqui, BSc
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Accepts sNDA for Taletrectinib in ROS1-Positive NSCLC
2
Achieving a “Functional Cure” With Multiple Myeloma Therapy
3
Epigenetic Priming and Immunotherapy Synergy Across the Lymphoma Space
4
ASCO Updates 340B Policy Statement to Expand Access, Improve Transparency
5